Notably, the use of highly selective biologic inhibitors of IL-1/IL-1R signaling (i.e., anakinra and canakinumab) have improved glomerular function in humans and experimental models of diabetic nephropathy [36,37]. The gene discussed is IL1A; the disease is diabetic kidney disease.